Verrica Pharmaceuticals Inc. (VRCA) stock
VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.56−0.16 (-4.30%)
Close on Nov 13, 2026Market cap $61.16MP/E –Yield –
Verrica Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Verrica Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was -184.2%. For fiscal 2025 it was -34.2%, against -871.3% the year before. The highest annual figure on record is -34.2% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -34.2% | +837.0 |
| FY2024 | Dec 31, 2024 | -871.3% | +412.1 |
| FY2023 | Dec 31, 2023 | -1283.4% | −1047.6 |
| FY2022 | Dec 31, 2022 | -235.8% | +21.8 |
| FY2021 | Dec 31, 2021 | -257.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -176.0% | −187.3 |
| Q2 FY2026 | Jun 30, 2026 | -223.4% | −235.3 |
| Q1 FY2026 | Mar 31, 2026 | -193.4% | +43.0 |
| Q4 FY2025 | Dec 31, 2025 | -141.2% | +3175.6 |
| Q3 FY2025 | Sep 30, 2025 | 11.3% | +305.1 |
| Q2 FY2025 | Jun 30, 2025 | 11.9% | +498.0 |
| Q1 FY2025 | Mar 31, 2025 | -236.4% | +927.4 |
| Q4 FY2024 | Dec 31, 2024 | -3316.9% | −2496.9 |
| Q2 FY2024 | Jun 30, 2024 | -293.7% | +6088.7 |
| Q1 FY2024 | Mar 31, 2024 | -486.1% | +18673.3 |
| Q4 FY2023 | Dec 31, 2023 | -1163.8% | +7970.0 |
| Q3 FY2023 | Sep 30, 2023 | -819.9% | −837.3 |
| Q2 FY2023 | Jun 30, 2023 | -6382.4% | −2120.3 |
| Q1 FY2023 | Mar 31, 2023 | -19159.5% | −17440.2 |
| Q4 FY2022 | Dec 31, 2022 | -9133.8% | −9134.3 |
| Q3 FY2022 | Sep 30, 2022 | 17.4% | – |
| Q2 FY2022 | Jun 30, 2022 | -4262.1% | – |
| Q1 FY2022 | Mar 31, 2022 | -1719.3% | – |
| Q1 FY2021 | Mar 31, 2021 | 0.5% | – |
See a number that looks wrong?